India CRDMO Market
Description
India CRDMO Market, By Service Type (Discovery Services, Preclinical & Clinical Development, Manufacturing Services); By Therapeutic Area (Oncology, Infectious Diseases, Cardiovascular & Metabolic Disorders); By End User (Pharmaceutical Companies, Biotechnology Firms, Academic & Research Institutes); By Region (East India, West India, South India, North India), Trend Analysis, Competitive Landscape & Forecast, 2019–2031India CRDMO Market Size Zooming 2.4X to Surpass USD 53 Billion by 2031
India CRDMO (Contract Research, Development, and Manufacturing Organization) Market is booming primarily due to a surging demand for CRDMO services and solutions driven by an increasing focus on cost efficiency and skilled workforce.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated India CRDMO (Contract Research, Development, and Manufacturing Organization) Market size by value at USD 22.61 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects India CRDMO Market size to boom at a robust CAGR of 13.10%, reaching a value of USD 53.53 billion by 2031. The rapid expansion of India CRDMO Market is propelled by a rising global demand for integrated drug development solutions, cost-effective manufacturing, and a skilled scientific workforce. The country’s robust infrastructure and favorable regulatory reforms attract international pharmaceutical and biotech firms seeking scalable, high-quality services. Growing interest in advanced modalities like biologics and mRNA therapies further boosts market expansion. Additionally, India’s strategic role in diversifying global supply chains amid geopolitical shifts enhances its appeal as a reliable partner for end-to-end research, development, and manufacturing operations.
Opportunity – Expansion into Biologics and RNA Therapeutics
India CRDMO Market is rapidly expanding into biologics and RNA therapeutics, driven by a global demand for advanced treatment modalities. Domestic firms are investing in high-end infrastructure, GMP-compliant facilities, and specialized talent to support monoclonal antibodies, biosimilars, and mRNA platforms. This shift enhances India’s value proposition beyond small molecules, attracting global biotech collaborations. As precision medicine and next-generation therapies gain momentum, India’s biologics and RNA capabilities position it as a competitive, scalable partner in the global drug development ecosystem.
Manufacturing Services Dominate India CRDMO Market
Manufacturing services constitute the largest segment of India CRDMO Market, driven by the country’s strong capabilities in large-scale production, cost efficiency, and regulatory compliance. Indian CRDMOs are widely recognized for their expertise in small molecule synthesis, API production, and formulation development. The segment benefits from robust infrastructure, skilled labor, and strategic partnerships with global pharmaceutical firms. As demand for scalable, high-quality manufacturing solutions grows, India’s dominance in the manufacturing segment continues to expand, reinforcing its role in global drug supply chains.
Impact of Escalating Geopolitical Tensions on India CRDMO Market
Escalating geopolitical tensions across the regions could disrupt pharmaceutical supply chains, delay cross-border drug approvals, and hinder clinical research collaborations. Trade restrictions and regulatory uncertainties may affect the flow of CRDMO contracts. Additionally, diverted the government’s focus and funding toward defense can reduce investments in public health initiatives. These challenges pose risks to consistent access, affordability, and innovations in India CRDMO Market, potentially slowing market growth despite rising demand for effective treatment across vulnerable populations.
Competitive Landscape
India CRDMO Market is highly fragmented, with numerous players serving the market. Major companies dominating the market are Syngene International, Jubilant Biosys, Piramal Pharma Solutions, Dr. Reddy’s Laboratories, GVK Biosciences, Sai Life Sciences, Aragen Life Sciences, Anthem Biosciences, TCG Lifesciences, Laurus Labs, and Divi’s Laboratories. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in India CRDMO Market.
The report's in-depth analysis provides information about growth potential, upcoming trends, and India CRDMO Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in India CRDMO Market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
India CRDMO (Contract Research, Development, and Manufacturing Organization) Market is booming primarily due to a surging demand for CRDMO services and solutions driven by an increasing focus on cost efficiency and skilled workforce.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated India CRDMO (Contract Research, Development, and Manufacturing Organization) Market size by value at USD 22.61 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects India CRDMO Market size to boom at a robust CAGR of 13.10%, reaching a value of USD 53.53 billion by 2031. The rapid expansion of India CRDMO Market is propelled by a rising global demand for integrated drug development solutions, cost-effective manufacturing, and a skilled scientific workforce. The country’s robust infrastructure and favorable regulatory reforms attract international pharmaceutical and biotech firms seeking scalable, high-quality services. Growing interest in advanced modalities like biologics and mRNA therapies further boosts market expansion. Additionally, India’s strategic role in diversifying global supply chains amid geopolitical shifts enhances its appeal as a reliable partner for end-to-end research, development, and manufacturing operations.
Opportunity – Expansion into Biologics and RNA Therapeutics
India CRDMO Market is rapidly expanding into biologics and RNA therapeutics, driven by a global demand for advanced treatment modalities. Domestic firms are investing in high-end infrastructure, GMP-compliant facilities, and specialized talent to support monoclonal antibodies, biosimilars, and mRNA platforms. This shift enhances India’s value proposition beyond small molecules, attracting global biotech collaborations. As precision medicine and next-generation therapies gain momentum, India’s biologics and RNA capabilities position it as a competitive, scalable partner in the global drug development ecosystem.
Manufacturing Services Dominate India CRDMO Market
Manufacturing services constitute the largest segment of India CRDMO Market, driven by the country’s strong capabilities in large-scale production, cost efficiency, and regulatory compliance. Indian CRDMOs are widely recognized for their expertise in small molecule synthesis, API production, and formulation development. The segment benefits from robust infrastructure, skilled labor, and strategic partnerships with global pharmaceutical firms. As demand for scalable, high-quality manufacturing solutions grows, India’s dominance in the manufacturing segment continues to expand, reinforcing its role in global drug supply chains.
Impact of Escalating Geopolitical Tensions on India CRDMO Market
Escalating geopolitical tensions across the regions could disrupt pharmaceutical supply chains, delay cross-border drug approvals, and hinder clinical research collaborations. Trade restrictions and regulatory uncertainties may affect the flow of CRDMO contracts. Additionally, diverted the government’s focus and funding toward defense can reduce investments in public health initiatives. These challenges pose risks to consistent access, affordability, and innovations in India CRDMO Market, potentially slowing market growth despite rising demand for effective treatment across vulnerable populations.
Competitive Landscape
India CRDMO Market is highly fragmented, with numerous players serving the market. Major companies dominating the market are Syngene International, Jubilant Biosys, Piramal Pharma Solutions, Dr. Reddy’s Laboratories, GVK Biosciences, Sai Life Sciences, Aragen Life Sciences, Anthem Biosciences, TCG Lifesciences, Laurus Labs, and Divi’s Laboratories. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in India CRDMO Market.
The report's in-depth analysis provides information about growth potential, upcoming trends, and India CRDMO Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in India CRDMO Market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Table of Contents
137 Pages
- India CRDMO Market, 2031
- 1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
- 2. Executive Summary
- 3. India CRDMO Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Rising Global Demand for Advanced Modalities
- 3.2.1.2. Cost-Efficient Small Molecule Manufacturing
- 3.2.1.3. Push to De-risk Global Supply Chains
- 3.2.2. Restraints
- 3.2.2.1. Limited Funding and High Capital Costs
- 3.2.2.2. Lagging ESG Compliance Standards
- 3.2.3. Opportunities
- 3.2.3.1. Expansion into Biologics and RNA Therapeutics
- 3.2.3.2. Strengthening R&D and Innovation Ecosystem
- 3.2.4. Challenges
- 3.2.4.1. Talent Shortage and Need for 6–7x Workforce Expansion
- 3.2.4.2. Regulatory Complexity and Approval Delays
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter’s Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
- 4. India CRDMO Market: Marketing Strategies
- 5. India CRDMO Market: Pricing Analysis
- 6. India CRDMO Market Overview
- 6.1. Market Size & Forecast, 2019–2031
- 6.1.1. By Value (USD Billion)
- 6.2. Market Share & Forecast
- 6.2.1. By Service Type
- 6.2.1.1. Discovery Services
- 6.2.1.2. Preclinical & Clinical Development
- 6.2.1.3. Manufacturing Services
- 6.2.2. By Therapeutic Area
- 6.2.2.1. Oncology
- 6.2.2.2. Infectious Diseases
- 6.2.2.3. Cardiovascular & Metabolic Disorders
- 6.2.3. By End User
- 6.2.3.1. Pharmaceutical Companies
- 6.2.3.2. Biotechnology Firms
- 6.2.3.3. Academic & Research Institutes
- 6.2.4. By Region
- 6.2.4.1. East India
- 6.2.4.2. West India
- 6.2.4.3. South India
- 6.2.4.4. North India
- 7. Competitive Landscape
- 7.1. List of Key Players and Their Offerings
- 7.2. India CRDMO Market Company Market Share Analysis, 2024
- 7.3. Competitive Benchmarking, By Operating Parameters
- 7.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
- 8. Impact of Escalating Geopolitical Tensions on India CRDMO Market
- 9. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
- 9.1. Syngene International
- 9.2. Jubilant Biosys
- 9.3. Piramal Pharma Solutions
- 9.4. Dr. Reddy’s Laboratories
- 9.5. GVK Biosciences
- 9.6. Sai Life Sciences
- 9.7. Aragen Life Sciences
- 9.8. Anthem Biosciences
- 9.9. TCG Lifesciences
- 9.10. Laurus Labs
- 9.11. Divi’s Laboratories
- 9.12. Other Prominent Players
- 10. Key Strategic Recommendations
- 11. Research Methodology
- 11.1. Qualitative Research
- 11.1.1.Primary & Secondary Research
- 11.2. Quantitative Research
- 11.3. Market Breakdown & Data Triangulation
- 11.3.1.Secondary Research
- 11.3.2.Primary Research
- 11.4. Breakdown of Primary Research Respondents, By Region
- 11.5. Assumptions & Limitations
- *Financial information of non-listed companies can be provided as per availability.
- **The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.
- List of Figures
- Figure 1 India CRDMO Segmentation
- Figure 2 India CRDMO Market Value Chain Analysis
- Figure 3 Company Market Share Analysis, 2024
- Figure 4 India CRDMO Market Size, By Value (USD Billion), 2019–2031
- Figure 5 India CRDMO Market Share, By Service Type, By Value, 2019–2031
- Figure 6 India CRDMO Market Share, By Therapeutic Area, By Value, 2019–2031
- Figure 7 India CRDMO Market Share, By End User, By Value, 2019–2031
- Figure 6 India CRDMO Market Share, By Region, 2019–2031
- List of Tables
- Table 1 India CRDMO Market Size, By Value (USD Billion), 2019–2031
- Table 2 India CRDMO Market Size, By Service Type, By Value, 2019–2031
- Table 3 India CRDMO Market Size, By Therapeutic Area, By Value, 2019–2031
- Table 4 India CRDMO Market Size, By End User, By Value, 2019–2031
- Table 5 India CRDMO Market Size, By Region, By Value, 2019–2031
- Table 6 Syngene International Company Overview
- Table 7 Syngene International Financial Overview
- Table 8 Jubilant Biosys Company Overview
- Table 9 Jubilant Biosys Financial Overview
- Table 10 Piramal Pharma Solutions Company Overview
- Table 11 Piramal Pharma Solutions Financial Overview
- Table 12 Dr. Reddy’s Laboratories Company Overview
- Table 13 Dr. Reddy’s Laboratories Financial Overview
- Table 14 GVK Biosciences Company Overview
- Table 15 GVK Biosciences Financial Overview
- Table 16 Sai Life Sciences Company Overview
- Table 17 Sai Life Sciences Financial Overview
- Table 18 Aragen Life Sciences Company Overview
- Table 19 Aragen Life Sciences Financial Overview
- Table 20 Anthem Biosciences Company Overview
- Table 21 Anthem Biosciences Financial Overview
- Table 22 TCG Lifesciences Company Overview
- Table 23 TCG Lifesciences Financial Overview
- Table 24 Laurus Labs Company Overview
- Table 25 Laurus Labs Financial Overview
- Table 26 Divi’s Laboratories Company Overview
- Table 27 Divi’s Laboratories Financial Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
